Despite the known cardiotoxic effects of doxorubicin and other anthracyclines, no evidence-
based guidelines exist for the surveillance and prevention of chemotherapy-induced …

Background: Several cardiovascular risk factors have been suggested to be associated with
anthracycline-induced cardiotoxicity, but their quantitative effects have not reached a …

Contemporary cancer therapies have dramatically improved cancer-free and overall survival
but have been accompanied by increasing cancer treatment–related cardiovascular toxicity …

Background Framingham risk score (FRS) is an effective tool for evaluating the 10-year risk
of cardiovascular diseases. However, the sensitivity of FRS for anthracycline-induced …

Background There is a lack of consensus to guide which breast cancer patients require left
ventricular function assessment (LVEF) prior to anthracycline therapy; the cost-effectiveness …

Background Cardiac assessment with multi-gated acquisition scan (MUGA) or
echocardiography (ECHO) is commonly employed prior to adjuvant anthracycline-based …

Anthracycline‐based chemotherapy is widely used in the management of breast cancer.
Despite the lack of clinical evidence, obtaining prechemotherapy left ventricular ejection …

Objetivo: Avaliar a alteração da função cardíaca em pacientes com câncer de mama
tratadas com quimioterapia. Métodos: Estudo observacional retrospectivo com coleta de …

Introduction Anthracycline-based and trastuzumab-containing regimens make a significant
impact on reducing the risk of distant metastases and improving cause-specific and overall …

As cancer therapies improve and the population as a whole ages, the number of elderly
patients with cancer rises. Aging cancer patients are particularly vulnerable to cardiotoxicity …